Mumbai-based Lupin Limited has entered into a partnership with Switzerland’s Sandoz Group AG to market and commercialize its biosimilar ranibizumab across multiple global regions.
Under the agreement, Sandoz will manage commercialization in the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will handle manufacturing and regulatory submissions. Sandoz will have exclusive marketing rights in most markets, with semi-exclusive rights in France, Australia, Vietnam, and Malaysia.
In a separate agreement, Sandoz will acquire exclusive rights to commercialize the biosimilar in Canada, while Lupin will continue to oversee manufacturing and regulatory processes.
Ranibizumab, a recombinant humanized IgG1 monoclonal antibody fragment, targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularisation (CNV).
“This collaboration reflects our shared commitment to expanding patient access to advanced biologic therapies worldwide,” said Thierry Volle, President EMEA & Emerging Markets, Lupin.